Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | QRFPR | Q96P65 | 3/20 | 0.51 |
| ▸ | CTSC | P53634 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706283 | 0.91 | MME (0.56) | MME | |
| SCHEMBL29542919 | 0.88 | PTPN2 (0.53) | PTPN1MME | |
| SCHEMBL29773185 | 0.88 | MME (0.59) | MME | |
| Hydrochloric Acid SCHEMBL31242481 | 0.87 | QRFPR (0.58) | FCER2PTPN1QRFPRCTSCMMP1 | |
| SCHEMBL1329813 | 0.86 | CTSC (0.59) | FCER2PTPN1QRFPRCTSCMMP1 | |
| SCHEMBL1329814 | 0.86 | CTSC (0.59) | FCER2PTPN1QRFPRCTSCMMP1 | |
| SCHEMBL30316218 | 0.86 | PTPN1 (0.58) | PTPN1 | |
| SCHEMBL8068326 | 0.85 | MME (0.61) | CTSCMME | |
| SCHEMBL8068319 | 0.85 | MME (0.61) | CTSCMME | |
| SCHEMBL8767006 | 0.83 | PTPN1 (0.60) | FCER2PTPN1MMP1MMECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | BICYCLETX LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| EP-4132481-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BicycleTX Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | BICYCLETX LIMITED (GB) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363718-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TSLP | TSLP, VIP, CCL2 | FCER2 64/4885PTPN1 1281/4885QRFPR 341/4885 |
| US-11866518-B2 | Bicyclic peptide ligands specific for TSLP | TSLP, VIP, CCL2 | FCER2 64/4885PTPN1 1281/4885QRFPR 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.